MRK240830P122000
- 4.15
- -0.35-7.78%
Merck & Co Newsroom
Merck & Co., Inc. (NYSE:MRK) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
IO Biotech Gets Data Monitoring Committee Recommendation to Continue Phase 3 Melanoma Study
Behind the Scenes of Merck & Co's Latest Options Trends
NuCana Gains Despite Trial Setback for Cancer Drug
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
Express News | Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target
Merck & Co Analyst Ratings
Merck Pulls Plug On Two Keytruda Late-Stage Studies On Underwhelming Data
Express News | Merck: First Patient Dosed in Phase III Myclad Trial of Oral Cladribine in Generalized Myasthenia Gravis
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (GMG)
Merck Stops Two More Cancer Trials Over Poor Results
Merck To Discontinue Phase 3 Keynote-867 Trial Of Keytruda Plus Stereotactic Body Radiotherapy For Patients With Stage I Or II Non-small Cell Lung Cancer And Phase 3 Keynote-630 Trial Of Keytruda As Adjuvant Treatment Of Patients With High-risk...
Express News | Merck & Co Inc - Keytruda Combo Does Not Improve Efs or Os in Keynote-867 Trial
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
Express News | Merck Provides Update on Phase 3 Keynote-867 and Keynote-630 Trials
New Medicare Drug Price Caps Could Help Seniors Save Over $1,000 a Year - AARP
Citic Securities Initiates Merck & Co. at Buy With $136 Price Target
MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate
Comparing Merck & Co With Industry Competitors In Pharmaceuticals Industry